FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a nucleic acid molecule for expressing a therapeutic protein in a subject, a pharmaceutical composition for treating a disease, deficiency, disorder or condition associated with a coagulation factor, and a method for providing expression of the coagulation factor in a patient. In one of the versions, the nucleic acid molecule contains in direction from 5' to 3': a first ITR, a gene cassette containing a nucleotide coding a therapeutic protein, and a second ITR.
EFFECT: invention extends the range of agents for the expression of the blood coagulation factor in the patient.
18 cl, 4 dwg, 9 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | 2019 |
|
RU2803163C2 |
| GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | 2017 |
|
RU2762257C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| METHODS FOR AAV DETECTION | 2017 |
|
RU2771622C2 |
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| IMPROVED FVIII FUSION PROTEIN AND ITS USE | 2019 |
|
RU2789085C2 |
| IMPROVEMENT OF CLINICAL PARAMETERS THROUGH FACTOR VIII EXPRESSION | 2019 |
|
RU2799048C2 |
| TREATMENT METHODS FOR HEMOPHILIA A | 2019 |
|
RU2812863C2 |
| MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
